Both public and commercial health insurers are now recognizing the challenges and complexity of effective diabetes management and how current and evolving technologies such as CGM, sensor-augmented insulin pump devices and now, and automated insulin delivery systems can dramatically reduce patient burden and the increasing costs associated with uncontrolled diabetes. This evidence concerns the gene INS and diabetes mellitus.